Company news

AstraZeneca PLC news in 2024

AstraZeneca PLC's news releases, calls and decks from 2024, newest first.

View company

Dato-DXd NSQ NSCLC application withdrawn in EU

December 24, 2024

Tagrisso approved in EU based on LAURA trial

December 23, 2024

Imfinzi approved in US for limited-stage SCLC

December 5, 2024

AstraZeneca appoints Iskra Reic EVP International

December 4, 2024

Truqap improved rPFS in advanced prostate cancer

November 25, 2024

Tagrisso recommended for EU approval - LAURA

November 18, 2024

AstraZeneca invests $3.5 billion in US

November 12, 2024

KOMET Phase III trial met primary endpoint

November 12, 2024

Dato-DXd new BLA submitted, NSQ BLA withdrawn

November 12, 2024

9M and Q3 2024 Results

November 12, 2024

Tezspire nasal polyps trial met primary endpoints

November 8, 2024

AZN share price movement

November 5, 2024

AZN China President under investigation

October 30, 2024

Wainzua recommended for approval in the EU

October 21, 2024

AstraZeneca licenses lipid lowering Lp(a) asset

October 7, 2024

Tagrisso US approval in unresectable lung cancer

September 26, 2024

Fasenra recommended for EU approval in EGPA

September 23, 2024

Final OS results reported for TROPION-Breast01

September 23, 2024

FluMist approved for self-administration in US

September 20, 2024

Fasenra EGPA US FDA approval

September 18, 2024

Imfinzi approved in US for resectable lung cancer

August 16, 2024

AstraZeneca prices a €1.4bn bond offering

July 30, 2024

Stabilisation Notice - ASTRAZENECA

July 29, 2024

Calquence fixed-duration combo improved 1L CLL PFS

July 29, 2024

ODAC reviewed Imfinzi in resectable lung cancer

July 26, 2024

Half-year Report

July 25, 2024

Acquisition of Amolyt Pharma completed

July 15, 2024

Lynparza & Imfinzi positive CHMP in endometrial

July 1, 2024

Update on Imfinzi ADJUVANT BR.31 trial

June 25, 2024

Imfinzi improved EFS and OS in bladder cancer

June 25, 2024

Update on CAPItello-290 Phase III trial

June 18, 2024

Imfinzi approved in the US for endometrial cancer

June 17, 2024

Acquisition of Fusion completed

June 5, 2024

Tagrisso plus chemo recommended for approval in EU

June 3, 2024

Dato-DXd improved OS in nonsquamous lung cancer

May 28, 2024

AstraZeneca to deliver $80bn revenue by 2030

May 21, 2024

AstraZeneca to manufacture ADCs in Singapore

May 20, 2024

SUPERNOVA Trial Met COVID-19 prevention endpoint

May 16, 2024

AstraZeneca completes Cellectis equity investment

May 7, 2024

Calquence combination improved PFS in 1L MCL

May 2, 2024

Truqap recommended for EU breast cancer approval

April 29, 2024

Enhertu improved PFS in HER2-low and ultralow

April 29, 2024

AstraZeneca increases 2024 dividend by 7%

April 11, 2024

Enhertu approved in US for HER2+ solid tumours

April 8, 2024

Imfinzi improved OS & PFS in limited-stage SCLC

April 5, 2024

Voydeya approved in US

April 2, 2024

FDA accepts Dato-DXd BLA for breast cancer

April 2, 2024

Ultomiris approved in the US for NMOSD

March 25, 2024

AstraZeneca to acquire Fusion

March 19, 2024

AstraZeneca to acquire Amolyt

March 14, 2024

Older news releases →

Calls in 2024

Decks in 2024